XERS Nasdaq Pharmaceutical Preparations Financials FY2020βFY2025
Xeris Biopharma Holdings, Inc. had $292M of revenue in fiscal 2025, up 43.7% on the year before. Over five years, revenue changed +70.2% a year on average.
Last close Β· Oct 23, 2026
$10.20
6.1%Hi! I read Xeris Biopharma Holdings, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+43.7%
Yes. Sales grew 43.7% last year.
Does it make a profit?
0.2%
A little. It keeps 0.2% of every sale as profit.
Is debt under control?
4.2x
Heavy. Repaying its debt would take 4.2 years of operating profit.
How healthy are the accounts?
7 / 8
Solid. It passes 7 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Xeris Biopharma Holdings, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 7, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 8, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 7, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 8, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Jan 10, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 8, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Xeris Biopharma Holdings, Inc. had $292M of revenue in fiscal 2025, up 43.7% on the year before. Over five years, revenue changed +70.2% a year on average. Its operating margin was 8.5%, up 25.1Β pts: of every 100 in sales, about 9 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Xeris Biopharma Holdings, Inc. made $0.6M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Xeris Biopharma Holdings, Inc. owes $109M more than it holds in cash, about 4.2 years of operating profit.
Cash, debt and the ratios that show how comfortably Xeris Biopharma Holdings, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $102M | $122M | $72.5M | $71.6M | $111M |
| Debt incl. finance leases | $88.1M | $187M | $191M | $232M | $220M |
| Net debt / EBITDA | β | β | β | β | 4.2x |
| Debt / equity | 0.9x | 4.1x | β | β | 16.1x |
| Interest coverage | β16.0x | β5.8x | β1.7x | β1.1x | 0.9x |
| Current ratio | 1.8x | 2.5x | 1.6x | 1.7x | 2.2x |
| Quick ratio | 1.6x | 2.2x | 1.2x | 1.2x | 1.6x |
| Total assets | $304M | $345M | $323M | $323M | $384M |
| Total liabilities | $209M | $299M | $329M | $353M | $370M |
| Shareholders' equity | $95.2M | $45.2M | β$6.8M | β$29.6M | $13.7M |
| Net debt (β = net cash) | β$14.4M | $65.1M | $118M | $160M | $109M |
KIRA Β· Its return on capital was 20.2%: every 100 invested in the business earned about 20 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Xeris Biopharma Holdings, Inc. passes 7 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 3 / 8 | 3 / 8 | 4 / 8 | 7 / 8 |
| Accruals ratio | β6.6% | β11.7% | 2.5% | β4.6% | β5.5% | β7.9% |
| Altman Z'' | β5.04 | β5.62 | β4.53 | β5.93 | β6.20 | β2.99 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $20.4M | $49.6M | $110M | $164M | $203M | $292M |
| Research and development | $20.9M | $25.2M | $21.0M | $22.3M | $25.6M | $31.2M |
| Operating income | β$83.5M | β$115M | β$81.9M | β$44.0M | β$33.6M | $24.9M |
| Interest expense | $10.7M | $7.2M | $14.1M | $26.6M | $30.5M | $29.1M |
| Pretax income | β | β$123M | β$96.1M | β$63.5M | β$57.1M | $0.6M |
| Income tax | β$0.1M | $0.0M | β$1.4M | β$1.2M | β$2.3M | $0.0M |
| Net income | β$91.1M | β$123M | β$94.7M | β$62.3M | β$54.8M | $0.6M |
| Net income to common | β | β | β | β$62.3M | β$54.8M | $0.6M |
| Diluted EPS | β$2.14 | β$1.55 | β$0.70 | β$0.45 | β$0.37 | $0.00 |
| Diluted shares | 0.04B | 0.08B | 0.14B | 0.14B | 0.15B | 0.17B |
| Cash flow | ||||||
| Cash from operations | β$80.6M | β$95.5M | β$103M | β$47.0M | β$37.0M | $28.6M |
| Capital expenditure | $0.4M | $1.1M | β | β | β | β |
| Free cash flow | β$80.9M | β$96.6M | β | β | β | β |
| Depreciation and amortization | $1.5M | $1.3M | $1.4M | $1.5M | $1.2M | $1.3M |
| Stock-based compensation | $8.3M | $11.4M | $12.2M | $10.7M | $18.4M | $22.4M |
| Balance sheet | ||||||
| Cash and short-term investments | $134M | $102M | $122M | $72.5M | $71.6M | $111M |
| Total debt | $87.0M | $88.1M | $187M | $191M | $232M | $220M |
| Current assets | $152M | $143M | $187M | $156M | $168M | $240M |
| Current liabilities | $28.2M | $79.0M | $73.6M | $95.2M | $100M | $110M |
| Inventory | $8.4M | $18.1M | $24.7M | $38.8M | $48.2M | $68.7M |
| Property and equipment, net | $6.7M | $6.6M | $5.5M | $6.0M | $5.6M | $4.9M |
| Goodwill | $0.0M | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M |
| Intangible assets | $0.0M | $131M | $121M | $110M | $98.9M | $88.1M |
| Total assets | $159M | $304M | $345M | $323M | $323M | $384M |
| Total liabilities | $125M | $209M | $299M | $329M | $353M | $370M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $33.8M | $95.2M | $45.2M | β$6.8M | β$29.6M | $13.7M |
| Margins | ||||||
| Operating margin | β408.8% | β232.2% | β74.3% | β26.8% | β16.6% | 8.5% |
| EBITDA margin | β401.7% | β229.5% | β73.1% | β25.9% | β16.0% | 9.0% |
| Net margin | β446.0% | β247.5% | β85.9% | β38.0% | β27.0% | 0.2% |
| FCF margin | β396.1% | β194.8% | β | β | β | β |
| Returns | ||||||
| Return on capital | β | β112.5% | β58.7% | β31.1% | β20.3% | 20.2% |
| Return on capital employed | β63.8% | β51.1% | β30.2% | β19.4% | β15.1% | 9.1% |
| Return on equity | β270.0% | β190.3% | β134.8% | β324.2% | β | β |
| Return on assets | β57.3% | β53.0% | β29.2% | β18.7% | β17.0% | 0.2% |
| Return on tangible equity | β270.0% | β | β | β | β | β |
| Growth | ||||||
| Revenue growth | β | 142.7% | 122.3% | 48.7% | 23.9% | 43.7% |
| Share count change | β | 85.3% | 71.6% | 1.5% | 6.6% | 17.7% |
| Financial health | ||||||
| Net debt / EBITDA | β | β | β | β | β | 4.2x |
| Debt / equity | 2.6x | 0.9x | 4.1x | β | β | 16.1x |
| Interest coverage | β7.8x | β16.0x | β5.8x | β1.7x | β1.1x | 0.9x |
| Current ratio | 5.4x | 1.8x | 2.5x | 1.6x | 1.7x | 2.2x |
| Quick ratio | 5.1x | 1.6x | 2.2x | 1.2x | 1.2x | 1.6x |
| Capital allocation | ||||||
| Capex / revenue | 1.8% | 2.2% | β | β | β | β |
| Stock comp / revenue | 40.5% | 23.0% | 11.0% | 6.5% | 9.0% | 7.7% |
| Quality scores | ||||||
| Piotroski F-score | β | 4.0 | 3.0 | 3.0 | 4.0 | 7.0 |
| Altman Z'' | β5.0 | β5.6 | β4.5 | β5.9 | β6.2 | β3.0 |
| Accruals ratio | β6.6% | β11.7% | 2.5% | β4.6% | β5.5% | β7.9% |
Source: SEC EDGAR XBRL filings (CIK 0001867096). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
